CAS:1953-04-4 C17H22BrNO3 Galantamine Hydrobromide
Min.Order / FOB Price:Get Latest Price
| 500 Gram |
Negotiable |
- Min.Order :500 Gram
- Purity: 99%
- Payment Terms : L/C,T/T,
Keywords
CAS:1953-04-4 C17H22BrNO3 Galantamine Hydrobromide CAS:1953-04-4 C17H22BrNO3 CAS:1953-04-4
Quick Details
- Appearance:white poweder
- Application:CAS:1953-04-4 C17H22BrNO3 Galantamine Hydrobromide
- PackAge:Plastic vacuum packaging bag or bucket
- ProductionCapacity:1|Metric Ton|Day
- Storage:under the cool and dry area
- Transportation:by express or by sea
Superiority:
| Galantamine Hydrobromide Basic information |
| Product Name: | Galantamine Hydrobromide |
| Synonyms: | NIVALIN;NIVALIN, HBR;4A,5,9,10,11,12-HEXAHYDRO-3-METHOXY-11-METHYL-6H-BENZOFURO[3A,3,2-EF][2]BENZAZEPIN-6-OL HYDROBROMIDE;GALANTAMINE HBR;GALANTAMINE HYDROBROMIDE;GALANTHAMIDE HYDROBROMIDE;GALANTHAMINE HBR;GALANTHAMINE HYDROBROMIDE |
| CAS: | 1953-04-4 |
| MF: | C17H22BrNO3 |
| MW: | 368.27 |
| EINECS: | 217-780-5 |
| Product Categories: | Alkaloids;Alkaloids (Others);Biochemistry;Functional Products;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;API's;Acetylcholine receptor;API;Chiral Reagents;Reminyl;Other APIs;Pharmaceutical intermediates |
| Mol File: | 1953-04-4.mol |
|
|
|
| Galantamine Hydrobromide Chemical Properties |
| mp | 256 °C |
| refractive index | -95 ° (C=1.4, H2O) |
| storage temp. | −20°C |
| Merck | 4340 |
| CAS DataBase Reference | 1953-04-4(CAS DataBase Reference) |
| Safety Information |
| Hazard Codes | T |
| Risk Statements | 25 |
| Safety Statements | 45-36/37/39-22 |
| RIDADR | UN 2811 6.1/PG 3 |
| WGK Germany | 3 |
| RTECS | DF8075000 |
| MSDS Information |
| Provider | Language |
|---|---|
| SigmaAldrich | English |
| Galantamine Hydrobromide Usage And Synthesis |
| Outline |
Galantamine hydrobromide also called as 11-methyl-3-methoxy -4a, 5, 9, 10, 11, 12-hexahydro-6H- benzene and furan [3a, 3, 2-ef] [2] benzazepine-6-ol hydrobromide, is an alkaloid isolated from Lycoris plants. In the 1960 s, China had first successfully isolated it from domestic Medicago Lycoris and Lycoris radiata, and had recorded into the Chinese Pharmacopoeia in 1977. The hydrobromide salt is white crystalline powder and is odorless with bitter taste. It is soluble in water, slightly soluble in ethanol but insoluble in chloroform, acetone, and ether. The absorption coefficient (50 ug in 1 ml of water): at 289nm wavelength, it has an absorption coefficient of 79.6 ~ 86.2. It is mainly applied to myasthenia gravis, poliomyelitis sequelae and resting stage as well as being used for the treatment of children with cerebral paralysis, polyneuritis, radiculitis and sensory motor disorders caused by nerve disorders or trauma. It is clinically also used for the treatment of Alzheimer's disease as well as treatment of dementia and memory disorders caused by the organic disease of the brain with significant therapeutic effect. Galantamine is a kind of phenanthridine alkaloids discovered by the Soviet scholars 50 years ago. It is the inhibitor of the reversible cholinesterase (ChE) and can selectively inhibit the real cholinesterase (AChE). Galantamine belongs to the second generation of acetylcholinesterase inhibitor drugs with its pharmaceutical composition being same as the extracted alkaloids of the European Mountain narcissus bulb. This kind of herbal medicine has already had a history of 30 years of clinical application in some countries and regions for the treatment of reversal neuromuscular blockade, myasthenia gravis, and children with cerebral palsy psychosis. |
| Cholinesterase inhibitors |
Galantamine hydrobromide is the hydrobromide salt of galantamine and is a cholinesterase inhibitor can be extracted from Amaryllidaceae Lycoris plant. The III-phase clinical trials in the United Kingdom in 1998 have showed that this drug had dual mechanism of action of both inhibiting acetylcholinesterase and regulating nicotinic receptors. Therefore, galantamine can improve the cognitive abilities of Alzheimer's patients and has been already applied as the drug of the treatment of mild to severe Alzheimer's disease (AD) drugs and has entered into market in EC countries. "Chinese Pharmacopoeia" has included the both the raw material and injection of galantamine hydrobromide. It is clinically mainly used for the treatment of poliomyelitis (polio) sequelae, muscular dystrophy and myasthenia gravis. It can be used to substitute neostigmine methyl-sulfate for antagonism of tubocurarine but with weak performance with the usage amount being ten times as high as the usage amount of neostigmine methyl-sulfate. Intravenous injection of 0.5 mg/kg of galantamine hydrobromide can quickly reverse the central anticholinergic effects caused through injection of scopolamine hydrobromide. It can also be used for treating children cerebral palsy, traumatic sensorimotor disorders, multiple neuritis and radiculitis. The above information is edited by the Chemicalbook of Dai Xiongfeng. |
| Physical and Chemical Properties | It is white crystalline powder and is odorless with bitter taste. It is soluble in water, slightly soluble in ethanol and insoluble in acetone, chloroform, ether and benzene. |
| Extracting Lycoris galantamine hydrobromide |
Galantamine hydrobromide can be extracted from Amaryllidaceae plant Lycoris radiata with the process of extraction, separation and preparation as below: The first step: the extract of total alkaloids Step two: The separation of galantamine Step three: Preparation of galanthamine hydrobromide |
| Pharmacological effects | Galantamine hydrobromide is a kind of tertiary amino alkaloid and is a reversible competitive inhibitor of cholinesterase. With the deepened understanding of the Alzheimer’s disease (AD) pathogenesis, people have started the study of using this product for treating AD in the early 1980s. In 1987, the United States scholars Bonnie had first successfully receive a patent of applying galantamine hydrobromide for treatment of AD. After this, many countries, one after another, have carried out related pharmacological, pharmacodynamic and pharmacokinetic studies related to it. This result had showed that galantamine hydrobromide, as the second-generation cholinesterase inhibitors, targeted on nerve synapses by competing with acetylcholine for binding to the cholinesterase and further blocking this enzymatic degradation of acetylcholine and therefore increasing the acetyl choline concentration inside the brain. |
| Pharmacokinetics | In 1989, Miliailova et al reported the pharmacokinetic studies of galantamine hydrobromide on humans. Studies have shown that, subcutaneous injection and oral administration can give similar excellent bioavailability. When being administered with 8-32 mg per day, the pharmacokinetics of this product exhibits a linear correlation. Oral administration of this tablets for 4 mg per time, 2 times per day has the serum half-life (t1/2) being 5-7 h, the average time for reaching peak (Tmax) being 0.5-1 h, and the protein binding rate being 20%. Nearly 50% of the drugs are excreted through urine in which 25% is proto-drug, 20% has been metabolized into O-demethylated galantamine- glucuronic acid, and 5% is the N-demethylated galantamine while those drugs which has been metabolized into galantamine or galantamine ketone only accounting for less than 2%. The ratios of the distribution level of this product in mouse tissue and its plasma levels were: erythrocytes 1.3, brain 2.1, liver 5.0, and the kidney concentration is 10 times as high as plasma concentration. |
| Indications | It is suitable for treatment of benign memory disorders, improving the directed memory, associative learning, image memory, nonsense figure recognition and also portraits recalling capability of the patients. It can also alleviate the symptom of dementia patients and also memory impairment caused by organic brain lesions. |
| Drug Interactions |
Galantamine hydrobromide can play a potential role on weakening the treatment efficacy of the anti-cholinergic drug. It has synergistic effect in combination with cholinomimetic effectors and other kinds of cholinesterase inhibitors. Combined with cimetidine ketoconazole may increase the bioavailability of the product. Combination with erythromycin can reduce the efficacy of this product. It has been reported that the combination between galantamine hydrobromide with digoxin can cause atrioventricular block |
| Adverse reactions |
Nervous System: Common symptoms include fatigue, dizziness, headache, trembling, insomnia, dreaminess; and hypertonia, rate aphasia, hyperactivity, etc in some rare cases. Gastrointestinal system: nausea, vomiting, abdominal distension, abdominal pain and diarrhea, anorexia and weight loss as well as indigestion. Cardiovascular system: commonly bradycardia, arrhythmia; rarely hypotension. Blood system: commonly anemia; occasionally thrombocytopenia . Endocrine and metabolic systems: occasionally increased blood sugar; hypokalemia had also reported. |
| Contraindications |
Patients being allergic to galantamine hydrobromide are prohibited Galantamine, as a kind of cholinesterase inhibitors is prohibited during the process of anesthesia Patients with angina and bradycardia are disabled Patients with severe asthma or pulmonary dysfunction are disabled Patients of severe liver damage were banned Patients of severe kidney damage were disabled Patients with mechanical obstruction are disabled |
| Application |
It can be used for the treatment of neurological diseases and trauma-induced movement disorders, multiple neuritis, and radiculitis. Cholinesterase inhibitors can reverse the process of scopolamine-induced amnesia. |
| Chemical Properties | White to Off-White Powder |
| Usage | A selective acetylcholinesterase inhibitor. A therapeutic agent for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism. |
| Usage | Alzheimer treatment;Cholinesterase inhibitor |
| Usage | anticholinesterase, analgesic, antiAlzheimer |
| Biological Activity | Long-acting, centrally active acetylcholinesterase inhibitor (IC 50 = 410 nM) and allosteric potentiator at neuronal nicotinic ACh receptors. Prevents β -amyloid-induced apoptosis in SH-SY5Y and bovine chromaffin cells. Long-term administration reduces amyloid precursor protein deposition and neurodegeneration in a mouse model of Alzheimer's disease. |
Details:
| Galantamine Hydrobromide Basic information |
| Product Name: | Galantamine Hydrobromide |
| Synonyms: | NIVALIN;NIVALIN, HBR;4A,5,9,10,11,12-HEXAHYDRO-3-METHOXY-11-METHYL-6H-BENZOFURO[3A,3,2-EF][2]BENZAZEPIN-6-OL HYDROBROMIDE;GALANTAMINE HBR;GALANTAMINE HYDROBROMIDE;GALANTHAMIDE HYDROBROMIDE;GALANTHAMINE HBR;GALANTHAMINE HYDROBROMIDE |
| CAS: | 1953-04-4 |
| MF: | C17H22BrNO3 |
| MW: | 368.27 |
| EINECS: | 217-780-5 |
| Product Categories: | Alkaloids;Alkaloids (Others);Biochemistry;Functional Products;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;API's;Acetylcholine receptor;API;Chiral Reagents;Reminyl;Other APIs;Pharmaceutical intermediates |
| Mol File: | 1953-04-4.mol |
|
|
|
| Galantamine Hydrobromide Chemical Properties |
| mp | 256 °C |
| refractive index | -95 ° (C=1.4, H2O) |
| storage temp. | −20°C |
| Merck | 4340 |
| CAS DataBase Reference | 1953-04-4(CAS DataBase Reference) |
| Safety Information |
| Hazard Codes | T |
| Risk Statements | 25 |
| Safety Statements | 45-36/37/39-22 |
| RIDADR | UN 2811 6.1/PG 3 |
| WGK Germany | 3 |
| RTECS | DF8075000 |
| MSDS Information |
| Provider | Language |
|---|---|
| SigmaAldrich | English |
| Galantamine Hydrobromide Usage And Synthesis |
| Outline |
Galantamine hydrobromide also called as 11-methyl-3-methoxy -4a, 5, 9, 10, 11, 12-hexahydro-6H- benzene and furan [3a, 3, 2-ef] [2] benzazepine-6-ol hydrobromide, is an alkaloid isolated from Lycoris plants. In the 1960 s, China had first successfully isolated it from domestic Medicago Lycoris and Lycoris radiata, and had recorded into the Chinese Pharmacopoeia in 1977. The hydrobromide salt is white crystalline powder and is odorless with bitter taste. It is soluble in water, slightly soluble in ethanol but insoluble in chloroform, acetone, and ether. The absorption coefficient (50 ug in 1 ml of water): at 289nm wavelength, it has an absorption coefficient of 79.6 ~ 86.2. It is mainly applied to myasthenia gravis, poliomyelitis sequelae and resting stage as well as being used for the treatment of children with cerebral paralysis, polyneuritis, radiculitis and sensory motor disorders caused by nerve disorders or trauma. It is clinically also used for the treatment of Alzheimer's disease as well as treatment of dementia and memory disorders caused by the organic disease of the brain with significant therapeutic effect. Galantamine is a kind of phenanthridine alkaloids discovered by the Soviet scholars 50 years ago. It is the inhibitor of the reversible cholinesterase (ChE) and can selectively inhibit the real cholinesterase (AChE). Galantamine belongs to the second generation of acetylcholinesterase inhibitor drugs with its pharmaceutical composition being same as the extracted alkaloids of the European Mountain narcissus bulb. This kind of herbal medicine has already had a history of 30 years of clinical application in some countries and regions for the treatment of reversal neuromuscular blockade, myasthenia gravis, and children with cerebral palsy psychosis. |
| Cholinesterase inhibitors |
Galantamine hydrobromide is the hydrobromide salt of galantamine and is a cholinesterase inhibitor can be extracted from Amaryllidaceae Lycoris plant. The III-phase clinical trials in the United Kingdom in 1998 have showed that this drug had dual mechanism of action of both inhibiting acetylcholinesterase and regulating nicotinic receptors. Therefore, galantamine can improve the cognitive abilities of Alzheimer's patients and has been already applied as the drug of the treatment of mild to severe Alzheimer's disease (AD) drugs and has entered into market in EC countries. "Chinese Pharmacopoeia" has included the both the raw material and injection of galantamine hydrobromide. It is clinically mainly used for the treatment of poliomyelitis (polio) sequelae, muscular dystrophy and myasthenia gravis. It can be used to substitute neostigmine methyl-sulfate for antagonism of tubocurarine but with weak performance with the usage amount being ten times as high as the usage amount of neostigmine methyl-sulfate. Intravenous injection of 0.5 mg/kg of galantamine hydrobromide can quickly reverse the central anticholinergic effects caused through injection of scopolamine hydrobromide. It can also be used for treating children cerebral palsy, traumatic sensorimotor disorders, multiple neuritis and radiculitis. The above information is edited by the Chemicalbook of Dai Xiongfeng. |
| Physical and Chemical Properties | It is white crystalline powder and is odorless with bitter taste. It is soluble in water, slightly soluble in ethanol and insoluble in acetone, chloroform, ether and benzene. |
| Extracting Lycoris galantamine hydrobromide |
Galantamine hydrobromide can be extracted from Amaryllidaceae plant Lycoris radiata with the process of extraction, separation and preparation as below: The first step: the extract of total alkaloids Step two: The separation of galantamine Step three: Preparation of galanthamine hydrobromide |
| Pharmacological effects | Galantamine hydrobromide is a kind of tertiary amino alkaloid and is a reversible competitive inhibitor of cholinesterase. With the deepened understanding of the Alzheimer’s disease (AD) pathogenesis, people have started the study of using this product for treating AD in the early 1980s. In 1987, the United States scholars Bonnie had first successfully receive a patent of applying galantamine hydrobromide for treatment of AD. After this, many countries, one after another, have carried out related pharmacological, pharmacodynamic and pharmacokinetic studies related to it. This result had showed that galantamine hydrobromide, as the second-generation cholinesterase inhibitors, targeted on nerve synapses by competing with acetylcholine for binding to the cholinesterase and further blocking this enzymatic degradation of acetylcholine and therefore increasing the acetyl choline concentration inside the brain. |
| Pharmacokinetics | In 1989, Miliailova et al reported the pharmacokinetic studies of galantamine hydrobromide on humans. Studies have shown that, subcutaneous injection and oral administration can give similar excellent bioavailability. When being administered with 8-32 mg per day, the pharmacokinetics of this product exhibits a linear correlation. Oral administration of this tablets for 4 mg per time, 2 times per day has the serum half-life (t1/2) being 5-7 h, the average time for reaching peak (Tmax) being 0.5-1 h, and the protein binding rate being 20%. Nearly 50% of the drugs are excreted through urine in which 25% is proto-drug, 20% has been metabolized into O-demethylated galantamine- glucuronic acid, and 5% is the N-demethylated galantamine while those drugs which has been metabolized into galantamine or galantamine ketone only accounting for less than 2%. The ratios of the distribution level of this product in mouse tissue and its plasma levels were: erythrocytes 1.3, brain 2.1, liver 5.0, and the kidney concentration is 10 times as high as plasma concentration. |
| Indications | It is suitable for treatment of benign memory disorders, improving the directed memory, associative learning, image memory, nonsense figure recognition and also portraits recalling capability of the patients. It can also alleviate the symptom of dementia patients and also memory impairment caused by organic brain lesions. |
| Drug Interactions |
Galantamine hydrobromide can play a potential role on weakening the treatment efficacy of the anti-cholinergic drug. It has synergistic effect in combination with cholinomimetic effectors and other kinds of cholinesterase inhibitors. Combined with cimetidine ketoconazole may increase the bioavailability of the product. Combination with erythromycin can reduce the efficacy of this product. It has been reported that the combination between galantamine hydrobromide with digoxin can cause atrioventricular block |
| Adverse reactions |
Nervous System: Common symptoms include fatigue, dizziness, headache, trembling, insomnia, dreaminess; and hypertonia, rate aphasia, hyperactivity, etc in some rare cases. Gastrointestinal system: nausea, vomiting, abdominal distension, abdominal pain and diarrhea, anorexia and weight loss as well as indigestion. Cardiovascular system: commonly bradycardia, arrhythmia; rarely hypotension. Blood system: commonly anemia; occasionally thrombocytopenia . Endocrine and metabolic systems: occasionally increased blood sugar; hypokalemia had also reported. |
| Contraindications |
Patients being allergic to galantamine hydrobromide are prohibited Galantamine, as a kind of cholinesterase inhibitors is prohibited during the process of anesthesia Patients with angina and bradycardia are disabled Patients with severe asthma or pulmonary dysfunction are disabled Patients of severe liver damage were banned Patients of severe kidney damage were disabled Patients with mechanical obstruction are disabled |
| Application |
It can be used for the treatment of neurological diseases and trauma-induced movement disorders, multiple neuritis, and radiculitis. Cholinesterase inhibitors can reverse the process of scopolamine-induced amnesia. |
| Chemical Properties | White to Off-White Powder |
| Usage | A selective acetylcholinesterase inhibitor. A therapeutic agent for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism. |
| Usage | Alzheimer treatment;Cholinesterase inhibitor |
| Usage | anticholinesterase, analgesic, antiAlzheimer |
| Biological Activity | Long-acting, centrally active acetylcholinesterase inhibitor (IC 50 = 410 nM) and allosteric potentiator at neuronal nicotinic ACh receptors. Prevents β -amyloid-induced apoptosis in SH-SY5Y and bovine chromaffin cells. Long-term administration reduces amyloid precursor protein deposition and neurodegeneration in a mouse model of Alzheimer's disease. |
You Might Also Like
Related Searches
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View